High-Dose PPI Use in Clinical Practice

Introduction to High-Dose PPI Therapy

The American Gastroenterological Association recommends that high-dose PPIs should be reserved exclusively for patients with severe erosive esophagitis, esophageal ulceration, peptic stricture, or Zollinger-Ellison syndrome 1, 2

High-dose PPIs lack FDA approval and have never been studied in randomized controlled trials, yet up to 15% of PPI users receive higher-than-standard doses 2
Higher doses are more strongly associated with adverse effects including community-acquired pneumonia, hip fracture, and Clostridium difficile infection, though causality remains unproven 2

Patients with LA grade C/D erosive esophagitis, esophageal ulceration, or peptic stricture may require higher doses for 4-8 weeks to achieve better healing rates 3
The American Gastroenterological Association recommends that patients with Zollinger-Ellison syndrome should never be de-prescribed high-dose therapy 1, 4

Most patients on twice-daily dosing should be stepped down to once-daily PPI unless they have documented complicated GERD 2
After healing of severe erosive esophagitis, attempt dose reduction to standard once-daily maintenance 3

Do not continue high-dose therapy indefinitely without documented indication—regular review of ongoing need is essential 2
Do not empirically use high-dose PPIs for extraesophageal symptoms—these require objective testing off medication first 5

Patients on antithrombotics, anticoagulants, or NSAIDs at high risk for GI bleeding require only standard once-daily PPI dosing, not high-dose 1, 4
Standard once-daily PPI is sufficient for Barrett's esophagus management—high-dose therapy offers no additional cancer prevention benefit 3
While PPIs are first-line therapy for eosinophilic esophagitis, standard dosing typically achieves clinical response and histologic remission in 51-61% of patients 3